Four brokers raise Apotex Corp. price targets in Canadian dollars
Stifel, Desjardins, Canaccord Genuity and RBC all raised C$ price targets on Apotex Corp., per Dow Jones Newswires citing Baystreet ratings data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires, citing Baystreet, reports that four brokerages have revised their price targets on Canadian drugmaker Apotex Corp. Stifel lifted its target to C$43 from C$42, Desjardins Securities moved it to C$44 from C$41, Canaccord Genuity set C$44 from C$41.50, and RBC raised it to C$46 from C$43.
Stifel and Desjardins Securities maintained their Buy ratings.
why it matters
Changes like these reflect brokers' updated valuation views and usually concern a single stock. For the broader market the news is minor, and its effect on Apotex shares is likely limited.
tags
instruments
sources
- Apotex Corp. Price Target Raised to C$43.00/Share From C$42.00 by Stifel — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
- Apotex Corp. Price Target Raised to C$44.00/Share From C$41.00 by Desjardins Securities — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
- Apotex Corp. Price Target Raised to C$44.00/Share From C$41.50 by Canaccord Genuity — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
- Apotex Corp. Price Target Raised to C$46.00/Share From C$43.00 by RBC — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗